Kimia Biosciences マネジメント

マネジメント基準チェック /34

Kimia Biosciencesの CEO はSameer Goelで、 May2022年に任命され、の在任期間は 2.5年です。は、会社の株式の74.94%を直接所有しており、その価値は₹ 1.64B 。経営陣と取締役会の平均在任期間はそれぞれ2.5年と8.6年です。

主要情報

Sameer Goel

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	2.5yrs
CEOの所有権	74.9%
経営陣の平均在職期間	2.5yrs
取締役会の平均在任期間	8.6yrs

経営陣の近況

Recent updates

CEO報酬分析

Kimia Biosciences の収益と比較して、Sameer Goel の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	₹29m
Jun 30 2024	n/a	n/a	-₹12m
Mar 31 2024	n/a	n/a	-₹53m
Dec 31 2023	n/a	n/a	-₹133m
Sep 30 2023	n/a	n/a	-₹148m
Jun 30 2023	n/a	n/a	-₹132m
Mar 31 2023	₹6m	n/a	-₹94m
Dec 31 2022	n/a	n/a	-₹46m
Sep 30 2022	n/a	n/a	-₹25m
Jun 30 2022	n/a	n/a	-₹29m
Mar 31 2022	₹6m	n/a	-₹37m
Dec 31 2021	n/a	n/a	-₹32m
Sep 30 2021	n/a	n/a	-₹14m
Jun 30 2021	n/a	n/a	₹34m
Mar 31 2021	n/a	n/a	₹51m
Dec 31 2020	n/a	n/a	₹52m
Sep 30 2020	n/a	n/a	₹49m
Jun 30 2020	n/a	n/a	₹30m
Mar 31 2020	₹444k	₹444k	₹14m
Dec 31 2019	n/a	n/a	₹21m
Sep 30 2019	n/a	n/a	₹40m
Jun 30 2019	n/a	n/a	₹38m
Mar 31 2019	₹5m	₹5m	₹39m

報酬と市場: Sameerの総報酬がIndian市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Sameerの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Sameer Goel (49 yo)

2.5yrs

在職期間

₹6,000,000

報酬

Mr. Sameer Goel has been Chief Executive Officer of Kimia Biosciences Limited since May 30, 2022. He serves as Managing Director of KIMIA Biosciences Pvt. Ltd.Mr. Goel has been the Chairman, Managing Dire...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Sameer Goel	CEO, Chairman of the Board & MD	2.5yrs	₹6.00m	74.94% ₹ 1.6b
Rakesh Chetani	Chief Financial Officer	1.2yrs	データなし	データなし
Subrat Satpathy	Chief Operating Officer	3.2yrs	₹6.55m	データなし
Mathura Joshi	Assistant General Manager of Finance & Accounts	no data	データなし	データなし
Pallavi Garg	Company Secretary & Compliance Officer	no data	データなし	データなし
Ruchita Mishra	Manager of Marketing	no data	データなし	データなし
Asit Bhalerao	Chief Human Resources Officer	3yrs	₹7.00m	データなし
Mukesh Sharma	Head of Research & Development	no data	₹3.59m	データなし
Rita Sarin	Advisor of Strategy & IPR Head of Intellectual Property Rights	no data	データなし	データなし

2.5yrs

平均在職期間

49yo

平均年齢

経験豊富な経営陣: 530313の経営陣は経験豊富であると考えられます ( 2.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Sameer Goel	CEO, Chairman of the Board & MD	8.7yrs	₹6.00m	74.94% ₹ 1.6b
Jagdeep Dhawan	Independent Non-Executive Director	8.7yrs	データなし	データなし
Richa Gupta	Independent Non-Executive Woman Director	8.6yrs	データなし	データなし
Vipul Goel	Non-Executive Non Independent Director	5.9yrs	データなし	0.000030% ₹ 655.8

8.6yrs

平均在職期間

47.5yo

平均年齢

経験豊富なボード: 530313の取締役会は経験豊富であると考えられます ( 8.6年の平均在任期間)。

Kimia Biosciences マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Insufficient new directors

Kimia Biosciences Limited Announces Chief Financial Officer Changes

Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2023

Kimia Biosciences Limited Announces Appointment of Ms. Mita Namonath Jha as an Additional Director (Non-Executive and Non-Independent Director )

Insufficient new directors

Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2022

Recent updates

New major risk - Financial position

First quarter 2025 earnings released: EPS: ₹0.30 (vs ₹0.57 loss in 1Q 2024)

New minor risk - Share price stability

Full year 2024 earnings released: ₹1.12 loss per share (vs ₹1.98 loss in FY 2023)

Kimia Biosciences Limited to Report Q4, 2024 Results on May 30, 2024

Insufficient new directors

New minor risk - Share price stability

Third quarter 2024 earnings released: ₹0.41 loss per share (vs ₹0.98 loss in 3Q 2023)

Kimia Biosciences Limited to Report Q3, 2024 Results on Feb 14, 2024

Second quarter 2024 earnings released: ₹0.52 loss per share (vs ₹0.18 loss in 2Q 2023)

Kimia Biosciences Limited to Report Q4, 2025 Results on May 30, 2025

Kimia Biosciences Limited Announces Chief Financial Officer Changes

Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2023

Kimia Biosciences Limited Announces Appointment of Ms. Mita Namonath Jha as an Additional Director (Non-Executive and Non-Independent Director )

First quarter 2024 earnings released: ₹0.57 loss per share (vs ₹0.23 profit in 1Q 2023)

Full year 2023 earnings released: ₹1.98 loss per share (vs ₹0.78 loss in FY 2022)

Insufficient new directors

Kimia Biosciences Limited to Report First Half, 2023 Results on Nov 14, 2022

Kimia Biosciences Limited to Report Q4, 2023 Results on Apr 12, 2023

Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2022

Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2022

First quarter 2023 earnings released: EPS: ₹0.23 (vs ₹0.07 in 1Q 2022)

Full year 2022 earnings released: ₹0.78 loss per share (vs ₹1.08 profit in FY 2021)

Kimia Biosciences Limited Appoints Sameer Goel as Chief Executive Officer

Kimia Biosciences Limited Announces Resignation of Suneel Kapoor as Chief Executive Officer

Kimia Biosciences Limited Announces Granted Permission to Manufacture and Marketing of Bemopedoic Acid Bulk Drug Under New Drug and Clincial Trials

Kimia Biosciences Limited Announces Appointment of Lakshay Prakash as Company Secretary

Insufficient new directors

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Kimia Biosciences Limited to Report Q3, 2022 Results on Feb 14, 2022

Insufficient new directors

Company Secretary & Compliance Officer Abhishek Pandey has left the company

First quarter 2022 earnings released: EPS ₹0.07 (vs ₹0.43 in 1Q 2021)

Full year 2021 earnings released: EPS ₹1.08 (vs ₹0.33 in FY 2020)

Investor sentiment improved over the past week

Kimia Biosciences Limited Bags Permission to Manufacture Bilastine API New Active Pharmaceutical Ingredient for Sale or for Distribution

Kimia Biosciences Limited Receives Permission to Manufacture New Active Pharmaceutical Ingredient for Sale or for Distribution

New 90-day low: ₹40.75

Third quarter 2021 earnings released: EPS ₹0.09 (vs ₹0.03 in 3Q 2020)

Kimia Biosciences Limited to Report Q3, 2021 Results on Feb 11, 2021

Investor sentiment improved over the past week

New 90-day high: ₹50.80

New 90-day high: ₹44.95

Market bids up stock over the past week

Market bids up stock over the past week

Kimia Biosciences Limited to Report Q2, 2021 Results on Nov 05, 2020

Kimia Biosciences Limited Approves Appointment of Vipul Goel as Non Executive, Non Independent Director

First quarter earnings released

New 90-day high - ₹33.80

Kimia Biosciences Limited to Report Q1, 2021 Results on Aug 18, 2020

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34